Clinical-stage partnerships Biotheryx is a clinical-stage biopharmaceutical company focused on first-in-class protein degraders with ongoing Phase 1 program BTX-9341 and a pipeline including SOS1 and PDE4 degraders, presenting a clear opportunity for collaboration with pharma companies seeking innovative oncology and inflammatory disease therapies.

Strategic collaborations Past partnerships noted with Incyte and a strong emphasis on Cereblon-based degradation platforms suggest openness to co-development or licensing deals that leverage Biotheryx’s PRODEGY platform and proprietary degraders to accelerate clinical programs.

Targeted oncology focus Critical targets such as CDK4/CDK6 and SOS1 for pan-KRAS cancers point to a translational value proposition for major oncology players seeking next-generation targeted therapies to overcome resistance to current CDK4/6 inhibitors.

Inflammation program BTX-10908 as a first-in-class SOS1-based degrader for pan-KRAS cancers and PDE4 degraders for inflammatory diseases expand the addressable market in inflammation, offering cross-indication collaboration and portfolio diversification.

Growth-ready profile With 11-50 employees, revenue in the mid-range for a biotech at this stage and substantial funding, Biotheryx presents as a scalable partner for late-stage collaborators and service providers seeking early access to innovative degraders.